TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: perceived size and perceived mass of objects
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Freedom from atrial fibrillation at 36 months post-ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Total Corneal Staining Score to Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Patient-Reported Ocular Dryness Score to Day 14
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite plasma glucose and hormone responses to a mixed meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose control coefficients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Referral rates of intervention or conservative treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: SO manometric change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum measured concentration of the analytes in plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve of the analytes in plasma (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time from dosing to the maximum concentration of the analytes in plasma (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mean Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular systolic dyssynchrony index (SDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bond Survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of Adhesive Remaining on the Tooth Surface After Bracket Debonding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Time Required for Adhesive Remnant Cleanup
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adequate or inadequate dose of sugammadex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disease Control Rate (DCR) at 4 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Anatomic Retinal Changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Days With Subcutaneous Octreotide as Rescue Medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical Remission at Week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in QTc Interval Based on Fridericia Correction Method (QTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients free of post-interventional complications
Endpoint domain: Adverse events/effects
Primary endpoint: Eating Disorder Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peak joint moments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Modified Sharp/Van Der Heijde Erosion Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Expectations regarding concussion reporting
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in z-BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Child Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change From Baseline on the PANSS NSFS at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with device- and/or procedure-related Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of procedures that achieved acute success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from Baseline Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Correlation of VLE results with histology for T1 EAC depth of invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correlation of VLE results with histology for staging T1 EAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sFLT-1/PlGF Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in International Prostate Symptom Score (IPSS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: % of patients whose diabetes resolves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximal tolerated dose of PRGN-3005
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Increase in activity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kappa scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seated CoP Shift Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Performance (Task Repetition Frequency)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with One or More Adverse Event(s)
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Risk profile development
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Functional Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tunnel enlargement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft signal intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cartilage morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 months progression free survival rates
Endpoint domain: Mortality/survival
Primary endpoint: Rate of complete resection for non-muscle-invasive bladder cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proper staging for muscle-invasive bladder cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of a Single Dose of Dabrafenib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Pain on Function (PoF)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain-free maximum mouth opening (MMO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to Treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 7-Day Point Prevalence Abstinence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: OZ439 AUC(0-168h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length-based weight estimation accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Phenotypes and sub-phenotypes of PBC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean speed of keystrokes on a repetitive finger movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean speed of movement on a peg movement task
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: local and systemic expression of cathelicidin (hCAP18/LL-37)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of emergency-department visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Recurrence rate of trigeminal neuralgia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients with neurological deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of subjects who do not receive an opioid prescription
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Condomless Anal Intercourse
Endpoint domain: Adverse events/effects
Primary endpoint: Cerebrospinal Fluid Beta-amyloid-42 Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 12-week modified immune-related response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of obliteration of injected varicosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in venous stasis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-operative and post-operative complications
Endpoint domain: Adverse events/effects
Primary endpoint: Significant cortical breaches (>4mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Procedures not completed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cmax Antibody Levels against Gingipains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of CTC before and after administration of anesthetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GSH/GSSG and Cys/CySS redox state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urinary output of taurine and sulfate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Caregiver Stress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ADHD rating scale IV inattention subscore
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Resilience Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent of radical prostatectomy tissue volume with high-grade prostatic intraepithelial neoplasia (HGPIN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Bone Mineral Density (BMD) of the Lumbar Spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of UGI and small-bowel examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Cumulus-Oocyte-Complexes Retrieved
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proinflammatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-inflammatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Severity of disease symptom menorrhagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Greater Than 50% Compliance to Exercise Regimen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Acceptability - Parent Satisfaction Survey
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of ACUITY X4 Spiral Leads Free From Complication Through 6 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of ACUITY X4 Straight Leads Free From Complication Through 6 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Pacing Capture Threshold (PCT) of RELIANCE 4-FRONT Leads at 3 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in the Plasma Soluble P-selectin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: large for gestational age infants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change in QTcF interval after study drugs administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Plasma piperaquine concentrations after study drugs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance Error Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Best-corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Retinal Sensitivity Assessed with Microperimetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of overactive bladder syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptomatic COVID-19 infection rate
Endpoint domain: Adverse events/effects
Primary endpoint: Knee Society Function Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Maximum Observed Drug Concentration (Cmax) of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration Curve (AUC) Time Zero to Infinity (AUC [0-∞]) of Midazolam
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and Tolerability Assessment of Serious Adverse Events (SAE) and Adverse Events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Viral load <400 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving Functional Remission at Week 26
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Participants Achieving Functional Remission at Week 52
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: intraoperative outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: pathological outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of HIV cases
Endpoint domain: Mortality/survival
Primary endpoint: Number of HCV seroconversions
Endpoint domain: Mortality/survival
Primary endpoint: Number of STD seroconversions
Endpoint domain: Mortality/survival
Primary endpoint: Symptom recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Recovery-15
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Overall Neck Disability Index (NDI) Score From Baseline
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Wrinkle severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antibiotic treatment prescribed at initial visit
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diversity of gut microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time taken to achieve gastric pH > 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intraocular inflammation grading
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients electing testing options
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Subjective appetite sensations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of sensitivities for detection of advanced neoplasias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Graft Function 30 day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Graft Survival 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Blood eicosanoid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urine eicosanoid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Apathy Inventory Scale - Clinician
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cumulative Incidence of Patients With Engraftment by Day +30 Following Transplant
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prefrontal hyperactivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Arterial OXT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venous OXT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Net Influx Constant (Ki) by FLT PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent Change in SUV by FLT PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage of Ki-67 Positive Tumor Cells in Surgical (Post-therapy) Sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percentage Change in Ki-67 Positive Cells Between Pre-therapy and Post-therapy Tumor Specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Externalizing Behavior Problems
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: gait time percentage for right lower limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gait time percentage of left lower limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time Required After Surgery to Reach Fitness for Discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychometric performance of the MIND score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nocturnal hypercapnia tcCO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Successful Regional Anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change of striae volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Willingness to take hypothetical pill
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Composite Overall Amount of Insulin Used
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in the Total Nasal Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from Major Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom from Target Lesion Revascularization
Endpoint domain: Adverse events/effects
Primary endpoint: Pressure measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Responders for Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Function Subscale in the Koos Scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Urinary-N-telopeptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: P1NP (Amino-terminal Propeptide of Type I Procollagen)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Aqueous concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in brain blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of major hypoglycaemic episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the plasma concentration vs time curve over the dosing interval, at steady state (AUCtau) of metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Metabolic Fatty Acid Profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: device success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of device
Endpoint domain: Adverse events/effects
Primary endpoint: number of cases of Vaginal cuff dehiscence
Endpoint domain: Adverse events/effects
Primary endpoint: Half life of COHb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histological amelioration of NASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Language organization prior to surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: invasive Disease Free Survival (iDFS)
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline in Corneal Staining Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Levels of Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scores on the feasibility scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hepatic Histological Improvement in NAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of acceptance of spinal anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes